Jan 31, 2025 · Digital Psychotherapeutics Market The global Digital Therapeutics (DTx) market is poised for explosive growth, rising from USD 4.8 billion in 2022 to USD 42.5 billion by 2032, at a CAGR of 24.4%.This expansion is fueled by technological advancements in mobile health (mHealth), AI-driven analytics, and personalized digital interventions.. Request a Sample Report Now to get Premium Insights ...

PharmiWeb.com - Global pharma news from the pharmaceutical industry, biotech, clinical research, life science & healthcare. Pharma Events Listings, Pharma Company Directory & pharma jobs.

Jan 20, 2025 · AI's Impact on Pharmaceutical Research and Drug Development Artificial intelligence (AI) has significantly enhanced the efficiency and precision of pharmaceutical research, bringing immense benefits to the drug discovery process. By leveraging machine learning algorithms, AI enables faster and more accurate identification of drug candidates.

Feb 5, 2025 · The global connected drug delivery devices market is undergoing rapid transformation, with its valuation set to surge from USD 448 million in 2022 to an anticipated USD 1.6 billion by 2028, marking an impressive Compound Annual Growth Rate (CAGR) of 23.6%. This significant growth insight, drawn from the latest comprehensive analysis by Future Market Insights, underscores the sector’s role in ...

Feb 4, 2025 · Farm Animal Drug Market The global farm animal drug market is experiencing significant growth and is projected to reach a market value of USD 19,442.9 million by the end of 2024. Recent forecasts indicate the market will continue its expansion at a steady Compound Annual Growth Rate (CAGR) of 5.5% from 2024 to 2034, with a projected market valuation of USD 33,211.3 million by 2034.

6 days ago · AOTI, INC. (AIM: AOTI), a medical technology group focussed on the durable healing of wounds and the prevention of amputations through its unique intermittent Topical Wound Oxygen (TWO 2) and Negative Pressure Wound (NEXA) therapies, is pleased to announce its unaudited trading update for the financial year ended 31 December 2024.. Group revenue for 2024 is expected to be in excess of $58.1m ...

Jan 14, 2025 · Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025. Paris, 13 th January, 2025: Pharmapack Europe & CPHI have outlined key trends for pharma in 2025, highlighting the return of funding liquidity—via increased VC investments and PE capital for M&A—alongside enhanced supply chain resilience as “The Good”.

Jan 15, 2025 · PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL ® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents. TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceuticals, Inc. ("Handa") (6620.TWO) announced that its U.S. subsidiary, Handa Therapeutics, LLC (the "Company"), has acquired PHYRAGO™ (dasatinib) tablets, a U.S. Food and Drug ...

5 days ago · Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of ...

Jan 17, 2025 · Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently exercised outstanding warrants held in Sa...